156 related articles for article (PubMed ID: 31018922)
1. Mogamulizumab Treatment Elicits Autoantibodies Attacking the Skin in Patients with Adult T-Cell Leukemia-Lymphoma.
Suzuki Y; Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Hiura M; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Clin Cancer Res; 2019 Jul; 25(14):4388-4399. PubMed ID: 31018922
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
[TBL] [Abstract][Full Text] [Related]
3. Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma.
Saito M; Ishii T; Urakawa I; Matsumoto A; Masaki A; Ito A; Kusumoto S; Suzuki S; Takahashi T; Morita A; Inagaki H; Iida S; Ishida T
Blood Adv; 2020 May; 4(10):2180-2191. PubMed ID: 32433748
[TBL] [Abstract][Full Text] [Related]
4. Mogamulizumab for the treatment of T-cell lymphoma.
Makita S; Tobinai K
Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
[TBL] [Abstract][Full Text] [Related]
5. CD8+ T-cell-mediated Interface Dermatitis after CCR4+ T-cell Depletion by Mogamulizumab Treatment of Adult T-cell Leukaemia/lymphoma.
Ito A; Sugita K; Adachi K; Hosoda Y; Motokura T; Yamamoto O
Acta Derm Venereol; 2017 Mar; 97(3):377-378. PubMed ID: 27786349
[No Abstract] [Full Text] [Related]
6. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
[TBL] [Abstract][Full Text] [Related]
8. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
9. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
Ureshino H; Kamachi K; Kimura S
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
[TBL] [Abstract][Full Text] [Related]
10. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
[No Abstract] [Full Text] [Related]
11. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
[TBL] [Abstract][Full Text] [Related]
12. Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.
Tanaka H; Fujiwara H; Ochi F; Tanimoto K; Casey N; Okamoto S; Mineno J; Kuzushima K; Shiku H; Sugiyama T; Barrett AJ; Yasukawa M
Clin Cancer Res; 2016 Sep; 22(17):4405-16. PubMed ID: 27091408
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features, Pathological Features, and Treatment Outcomes of 22 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated with a Humanized CCR4 Antibody (Mogamulizumab) at a Single Institution during a 6-year Period (2012-2018).
Kawano N; Yoshida N; Kawano S; Arakawa F; Miyoshi H; Yamada K; Nakashima K; Yoshida S; Kuriyama T; Tochigi T; Nakaike T; Shimokawa T; Yamashita K; Marutsuka K; Mashiba K; Kikuchi I; Ohshima K
Intern Med; 2019 Aug; 58(15):2159-2166. PubMed ID: 30996180
[TBL] [Abstract][Full Text] [Related]
14. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
de Lartigue J
Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
[TBL] [Abstract][Full Text] [Related]
16. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
17. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
Zamarin D; Hamid O; Nayak-Kapoor A; Sahebjam S; Sznol M; Collaku A; Fox FE; Marshall MA; Hong DS
Clin Cancer Res; 2020 Sep; 26(17):4531-4541. PubMed ID: 32586937
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of a Humanized CCR4 Antibody (Mogamulizumab) in 14 Patients with Aggressive Adult T-cell Leukemia-lymphoma Treated at a Single Institution During a Three-year Period (2012-2014).
Kawano N; Kuriyama T; Sonoda KH; Yoshida S; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
Intern Med; 2016; 55(11):1439-45. PubMed ID: 27250049
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
